AbSorber
Latest news
-
2011-10-31
Clinical use of XM-ONE® was highlighted at a symposium at the annual American Society of Histocompatibility and Immunogetetics (ASHI) meeting in New Orleans -
2011-05-11
New study confirms that XM-ONE® identifies kidney transplant recipients at increased risk for acute rejection. -
2011-04-10
AbSorber to host a Scientific Symposium at the American Transplant Congress in Philadelphia, PA -
2011-02-10
AbSorber and Olerup SSP has signed an exclusive distribution agreement for the Brazilian market, the world's second largest transplantation market after the US. Partner in Brazil is Genese Produtos Diagnosticos Ltda in Sao Paulo.
XM-ONE identifies patients at risk
XM-ONE, AbSorber's transplantation cross match, has proven to identify patients at risk of experiencing acute rejections after kidney transplantation. This was initially shown in 2009 when Breimer and co-workers published data from a multicenter study XM-ONE® (Breimer, M et al, Transplantation, Feb 2009). In a new publication from Johns Hopkins Medical School, Baltimore, MD (Jackson, AM et al, Transplantation, Apr 2011) these findings are confirmed.
AbSorber
AbSorber AB is a biotech company focused on developing products that increase the probability of transplantation success. XM-ONE®, the first AbSorber product on the market, is a CE-marked and FDA registered non-HLA transplantation crossmatch test kit. In contrast to current crossmatch testing, XM-ONE® rapidly detects antibodies specific for endothelial-specific antigens (AECA) as well as antibodies specific to major transplantation antigens. read more»
Highlighted Meeting
The clinical utility of XM-ONE was discussed at a symposium during the meeting - read the Newsletter here.
| Date: |
Oct 17-21, 2011 |
| Location: | New Orleans, USA |
Newsletter
Get information on XM-ONE® and stay tuned with AbSorber through our newsletter.